NCT05136833View on ClinicalTrials.gov

Evaluation of Efficacy and Safety of the Concomitant of RUTI® Immunotherapy With the Standard Treatment in TB Patients

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 1, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

December 31, 2022

Conditions
Tuberculosis
Interventions
BIOLOGICAL

RUTI® vaccine

Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in a total volum of 0.3mL.

BIOLOGICAL

Placebo

Normal saline will be used as a placebo.

Sponsors
All Listed Sponsors
collaborator

Fundació Institut Germans Trias i Pujol

OTHER

lead

Archivel Farma S.L.

INDUSTRY